期刊文献+

FimH_(1-156)融合基因的构建及其原核蛋白表达与纯化

Construction,prokaryotic expression and purification of FimH_(1-156) fusion protein
下载PDF
导出
摘要 目的构建含有与溶酶体膜蛋白2(LAMP-2)P41-49完全同源序列的尿路致病性大肠杆菌(UPEC)Ⅰ型菌毛FimH1-156为目的基因的原核载体,表达并纯化FimH1-156融合蛋白。方法采用PCR克隆pPKL241质粒获取FimH1-156基因,插入原核表达载体pET28a(+);将重组表达质粒转染感受态E.coli BL21(DE3),经IPTG诱导表达FimH1-156融合蛋白,超声裂解细菌,NiNTA层析法进行纯化,聚丙烯酰胺凝胶电泳(SDS-PAGE)分析、蛋白免疫印迹法(Western blot)对其进行鉴定。结果成功构建表达载体,经对融合蛋白表达条件的优化,在IPTG浓度为1mmol/L,诱导4h目的蛋白表达量最高,主要以包涵体形式存在;Western blot证实该FimH1-156融合蛋白可与抗6×His单克隆抗体发生结合反应。结论成功克隆FimH1-156融合蛋白表达基因并构建至原核表达载体,获得了包涵体纯化的FimH1-156融合蛋白,为下一步建立实验动物模型奠定了基础。 Objective To construct and express a prokaryotic expression vector carrying the gene of FimH 1-156 that comprises human lysosome membrane protein 2 P41-49 gene ,and to express and purify the fusion protein .Methods FimH1-156 gene was cloned from plasmid pPKL241 by PCR ,and inserted into vector pET-28a(+ ) to obtain prokaryotic expression plasmid pET-28a-FimH . After transforming Escherichia coli BL21(DE3) with pET-28a-FimH ,fusion protein FimH1-156 was expressed under induction .The target fusion protein was purified ,and its antigenicity was detected through Western blot .Results The expressed recombinant pro-tein was purified ,the expression of protein was the highest when IPTG was 1 mmol/L and 4h after induction ,it was expressed as include body form ,and the expressed protein was identified to react with monoclonal antibodies 6×His by Western blotting .Conclu-sion We cloned FimH1-156 fusion protein expressed genes successfully ,constructed prokaryotic expression vector ,and won the in-clusion body purification of FimH1-156 fusion protein .
出处 《重庆医学》 CAS CSCD 北大核心 2014年第5期589-591,共3页 Chongqing medicine
基金 国家自然科学基金资助项目(30971366) 重庆市国际合作项目(CSTC201110004) 第三军医大学科研课题(2011XLC37)
关键词 FIM H1 -156 融合蛋白 表达 纯化 FimH1 -156 fusion protein expression purification
  • 相关文献

参考文献9

  • 1Rashid T,Ebringer A. Autoimmunity in rheumatic disea-ses is induced by microbial infections via crossreactivity or molecular mimicry[J].Autoimmune Dis,2012.539282.
  • 2Kain R,Exner M,Brandes R. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis[J].{H}Nature Medicine,2008,(10):1088-1096.
  • 3Bower JM,Eto DS,Mulvey MA. Covert operations of uro-pathogenic Escherichia coli within the urinary tract[J].{H}TRAFFIC,2005,(1):18-31.
  • 4Connell I,Agace W,Klemm P. Type 1 fimbrial ex-pression enhances Escherichia coli virulence for the urina-ry tract[J].{H}Proceedings of the National Academy of Sciences(USA),1996,(18):9827-9832.
  • 5van Putten JW,van Haren EH,Lammers JW. Association between Wegener′s granulomatosis and Staphylococcus aureus infection[J].{H}European Respiratory Journal,1996,(9):1955-1957.
  • 6Kain R,Tadema H,McKinney EF. High prevalence of autoantibodies to hLAM P-2 in anti-neutrophil cyto-plasmic antibody-associated vasculitis[J].{H}Journal of the American Society of Nephrology,2012,(3):556-566.
  • 7Roth AJ,Brown MC,Smith RN. Anti-LAMP-2 anti-bodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis[J].{H}Journal of the American Society of Nephrology,2012,(3):545-555.
  • 8Fervenza FC,Specks U. Vasculitis:Will LAMP enlighten us about ANCA-associated vasculitis[J].Nat Rev Neph-rol,2012,(6):318-320.
  • 9尹晓琳,石新丽,魏林,王秀荣,马翠卿,冯惠东.尿路致病性大肠杆菌Ⅰ型菌毛fimH和fimC基因原核表达质粒的构建及表达[J].中国人兽共患病学报,2007,23(11):1131-1134. 被引量:5

二级参考文献10

  • 1Mulvey MA ,Lopez Boado YS , Wilson CL , et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichiacoli[J]. Science , 1998 ,282 (20) :149421497.
  • 2Kunin CM. Urinary tract infections in females[J]. Clin Infect Dis,1994,18: 1-12.
  • 3Ackermann RJ, Monroe PW. Bacteremic urinary tract infection in older people[J]. J Am Geriatr Soc,1996, 44 : 927-933.
  • 4Hooten TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infections in young women[J]. N Engl J Med, 1996,335: 468-474.
  • 5Donnenberg MS , Welch RA. Virulence determinants of Uropathogenic Escherichia coli in urinary tract infections molecularpathogenesis and clinical management [J]. American Socity for Microbiology , 1996 , 135-137.
  • 6Johnson JR , Stell AL. Extended virulence genotypes of Escherichia coli strains from patiens with urosepsis in relation to phylogency and host compromise[J]. J Infect Dis , 2000 , 181: 261-2721.
  • 7Schilling J D , Matthew S, Hultgren J. Structure and Function of Escherichia coli Type 1 Pill : New Insight into the Pathogenesis of Urinary Tract Infections[J]. J Infect Dis , 2001 ; 183 (Suppl 1) :S36-40.
  • 8Schembri M A , Kjaergaard K , Sokurenko E V ,et al. Molecular Characterization of the Escherichia coli fimH Adhesin[J ]. J Infect Dis ,2001 ,183 (Suppl 1) :S28-S311.
  • 9Langermann S, Palaszynski S , Barnhart M ,et al. Prevention of Mucosal Escherichia coli Infection by fimH - Based Systemic Vaccination[J]. Science ,1997 ,276 (25) :607-611.
  • 10Langermann S , Mollby R , Burlein J E , et al. Vaccination with fimH Adhesin Protects Cynomolgus Monkeys from Colonization and Infection by Uropathogenic Escherichia coli[J]. J Infect Dis,2000 ,181:774-778.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部